A treatment that combines engineered CAR-T cells targeting CD47 and inhibits secreted THBS2/THBS3 using antibodies may constitute a valuable therapeutic strategy to inhibit ovarian cancer progression. This evidence concerns the gene CD47 and ovarian cancer.